Pharmacokinetics and safety of coformulated bictegravir emtricitabine and tenofovir alafenamide in children aged 2 years and older with virologically suppressed HIV a phase 23 openlabel singlearm study

Simple item page
dc.article.end-page308en
dc.article.start-page300en
dc.citation.doi10.1016/S2352-3018(23)00327-2en
dc.contributor.authorC Rodriguezen
dc.contributor.authorE Natukundaen
dc.contributor.authorRenate Strehlauen
dc.contributor.authorE Venteren
dc.contributor.authorS Rungmaitreeen
dc.contributor.authorE et alen
dc.contributor.authorAfaaf Libertyen
dc.date.accessioned2025-04-13T11:49:39Z
dc.facultyFACULTY OF HEALTH SCIENCESen
dc.identifier.citationWOSen
dc.identifier.issn2352-3018en
dc.identifier.urihttps://hdl.handle.net/10539/44754
dc.journal.titlePharmacokinetics and safety of coformulated bictegravir emtricitabine and tenofovir alafenamide in children aged 2 years and older with virologically suppressed HIV a phase 23 openlabel singlearm studyen
dc.journal.volume11en
dc.titlePharmacokinetics and safety of coformulated bictegravir emtricitabine and tenofovir alafenamide in children aged 2 years and older with virologically suppressed HIV a phase 23 openlabel singlearm studyen
dc.typeJournal Articleen

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Journal Article.pdf
Size:
630.27 KB
Format:
Adobe Portable Document Format
Description:
Bitstream uploaded by REST Client
Download

Collections

Academic Wits Research Outputs (All submissions)